WP
MAZE

Woodline Partners’s Maze Therapeutics MAZE Stock Holding History

Woodline Partners’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.4M Sell
650,229
-385,000
-37% -$17M 0.07% 350
2025
Q4 		$42.9M Hold
1,035,229
– – 0.17% 165
2025
Q3 		$26.8M Buy
1,035,229
+94,529
+10% +$1.6M 0.13% 218
2025
Q2 		$11.5M Buy
940,700
+11,598
+1% +$121K 0.06% 392
2025
Q1 		$10.2M Buy
+929,102
New +$11.2M 0.07% 356

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners's MAZE Position: Q1 2026 in Review

Woodline Partners reduced its Maze Therapeutics (MAZE) stake by 37% in Q1 2026, selling an estimated $17M and leaving 650,229 shares worth $19.4M. The position accounts for 0.07% of the portfolio, ranked #350.

Woodline Partners first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $42.9M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Woodline Partners held 650,229 shares of Maze Therapeutics worth $19.4M as of Q1 2026.
  • Woodline Partners sold 385,000 Maze Therapeutics shares in Q1 2026, an estimated $17M.
  • Maze Therapeutics made up 0.07% of Woodline Partners's portfolio in Q1 2026, its #350 holding.
  • Woodline Partners first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Woodline Partners's Maze Therapeutics position peaked at $42.9M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.